Zoledronic Acid - CAS 118072-93-8
Catalog number: 118072-93-8
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C5H10N2O7P2
Molecular Weight:
272.09
COA:
Inquire
Targets:
PKC
Description:
Zoledronic acid induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho.
Purity:
>98%
Synonyms:
Zoledronate, CGP-4244
MSDS:
Inquire
InChIKey:
XRASPMIURGNCCH-UHFFFAOYSA-N
InChI:
InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
Canonical SMILES:
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
1.Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report.
Karahasanovic A1,2, Thorsteinsson AL3,4, Bjarnason NH5,6, Eiken P3,4. Osteoporos Int. 2016 Apr 14. [Epub ahead of print]
Cystic fibrosis (CF) is a serious autosomal recessive genetic disorder associated with chronic lung disease, malabsorption, malnutrition, pancreatic insufficiency and premature respiratory failure. Recent advances in medical science and technology have increased the lifespan of patients with CF, albeit with long-term consequences of the disease, such as osteoporosis, becoming of increasing significance. The medical treatment of osteoporosis in patients with CF or after organ transplantation is still being explored, and no clear guidelines regarding the best choice of bisphosphonate exist. We report a case of a young woman with CF, lung transplantation and low bone mass developing long-term leukopenia after treatment with zoledronic acid. The leukopenia, with a strong affection of the neutrocytes, lasted for 4 months and the condition only went into remission after granulocyte-colony stimulating factor (G-CSF) treatment. It is important to be aware of symptomatic leukopenia in immunosuppressive patients after treatment with zoledronic acid.
2.Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Fanale D1, Amodeo V1, Bazan V1, Insalaco L1, Incorvaia L1, Barraco N1, Castiglia M1, Rizzo S1, Santini D2, Giordano A3, Castorina S4, Russo A1. Oncotarget. 2016 Apr 13. doi: 10.18632/oncotarget.8722. [Epub ahead of print]
Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticancer role, by inhibiting cell adhesion, invasion, cytoskeleton remodelling and proliferation in MCF-7 breast cancer cells. In order to identify the molecular mechanisms and signaling pathways underlying the anticancer activity exerted by ZOL, we analyzed for the first time the microRNA expression profile in breast cancer cells. A large-scale microarray analysis of 377 miRNAs was performed on MCF7 cells treated with 10 μM ZOL for 24 h compared to untreated cells. Furthermore, the expression of specific ZOL-induced miRNAs was analyzed in MCF-7 and SkBr3 cells through Real-time PCR. Low-dose treatment with ZOL significantly altered expression of 54 miRNAs.
3.Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A1, Higuchi T1, Ozawa H1, Yanai A1, Miyagawa Y1, Murase K1, Imamura M1, Takatsuka Y1, Miyoshi Y2. Breast Cancer. 2016 Apr 4. [Epub ahead of print]
BACKGROUND: Bone-modifying agents are effective for treatment of breast cancer patients with bone metastases. Since their action is mediated through suppression of the osteoclast function, their efficacy can be determined by monitoring bone turnover markers. However, the clinical significance of these markers is yet to be compared.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PKC Products


CAS 102649-78-5 SC-9

SC-9
(CAS: 102649-78-5)

SC-9 is a potent activator of protein kinase C in the presence of Ca2+.

CAS 138489-18-6 Ro 31-8220 Mesylate

Ro 31-8220 Mesylate
(CAS: 138489-18-6)

Ro 31-8220 inhibits rat brain PKC activity with IC50 of 23 nM, and does not show any high degree of selectivity between PKC-α, PKC-β, PKC-γ, and PKC-ε.

CAS 133053-19-7 Go6983

Go6983
(CAS: 133053-19-7)

GO6983 is a potent protein kinase C (PKC) inhibitor. GO6893 displays cardioprotective properties; reduces polymorphonuclear leukocyte adherence and infiltration...

CAS 6865-14-1 (±)-Palmitoylcarnitine chloride

(±)-Palmitoylcarnitine chloride
(CAS: 6865-14-1)

(±)-Palmitoylcarnitine chloride, a long-chain acylcarnitine with both intracellular and extracellular roles, has a wide range of biological actions including th...

NSC305787 hydrochloride
(CAS: 53868-26-1)

NSC305787 hydrochloride is a small molecule inhibitor of PKC (IC50=8.3 μM) that directly inhibits ezrin protein as an approach to prevent tumor metastasis.

CAS 169939-94-0 Ruboxistaurin

Ruboxistaurin
(CAS: 169939-94-0)

Ruboxistaurin, also called as LY 333531, initially developed for the treatment of diabetic retinopathy, inhibits isolated enzymes PKCβI and PKCβII with a half-m...

CAS 137592-45-1 Bisindolylmaleimide II

Bisindolylmaleimide II
(CAS: 137592-45-1)

Bisindolylmaleimide II is a potent and ATP-competitive inhibitor of protein kinase C (PKC) (IC50 = 0.01 μM). It also displays an antagonistic effect on nicotini...

CAS 28399-31-7 FR 236924

FR 236924
(CAS: 28399-31-7)

FR 236924 is a selective PKCε activator with > 7-fold selectivity over other PKC isozymes. FR 236924 promotes glutamate release via presynaptic α7 nicotinic rec...

Chemical Structure

CAS 118072-93-8 Zoledronic Acid

Quick Inquiry

Verification code

Featured Items